Show simple item record

dc.contributor.authorFarquharson, Adam L
dc.contributor.authorPranesh, Nagarajan
dc.contributor.authorWitham, Gary
dc.contributor.authorSwindell, Ric
dc.contributor.authorTaylor, Malcolm B
dc.contributor.authorRenehan, Andrew G
dc.contributor.authorRout, Shantanu
dc.contributor.authorWilson, Malcolm S
dc.contributor.authorO'Dwyer, Sarah T
dc.contributor.authorSaunders, Mark P
dc.date.accessioned2009-03-16T16:35:25Z
dc.date.available2009-03-16T16:35:25Z
dc.date.issued2008-08-19
dc.identifier.citationA phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. 2008, 99 (4):591-6 Br. J. Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid18682713
dc.identifier.doi10.1038/sj.bjc.6604522
dc.identifier.urihttp://hdl.handle.net/10541/55796
dc.description.abstractPseudomyxoma peritonei (PMP) is a rare neoplastic process characterised by progressive intra-abdominal dissemination of mucinous tumour, and generally considered resistant to systemic chemotherapy. A phase II study in patients with advanced unresectable PMP was undertaken to evaluate the combination of systemic concurrent mitomycin C (7 mg m(-2) i.v. on day 1) and capecitabine (1250 mg m(-2) b.d. on days 1-14) in a 3-weekly cycle (MCap). Response was determined by semiquantitative assessment of disease volume on serial computed tomographic (CT) scans and serum tumour marker (CEA, CA125, CA19-9) changes at 12 weeks. Between 2003 and 2006, 40 patients were recruited through a national centre for the treatment of peritoneal surface tumours. At baseline, 23 patients had progressive disease and 17 had stable disease. Of 39 assessable patients, 15 (38%, 95% confidence intervals (CIs): 25, 54%) benefited from chemotherapy in the form of either reductions in mucinous deposition or stabilisation of progressive pretreatment disease determined on CT scan. Notably, two patients, originally considered unresectable, following MCap and re-staging underwent potentially curative cytoreductive surgery. Grade 3/4 toxicity rates were low (6%, 95% CIs: 4, 9%). Twenty out of 29 assessed patients (69%, 95% CIs: 51, 83%) felt that their Global Health Status improved during chemotherapy. This is the first trial to demonstrate an apparent benefit of systemic chemotherapy in patients with advanced unresectable PMP.
dc.language.isoenen
dc.subjectPsedomyxoma Peritoneien
dc.subjectChemotherapyen
dc.subjectCapecitabineen
dc.subjectMitomycin Cen
dc.subjectPMPen
dc.subjectPeritoneal Cancer
dc.subject.meshAdenocarcinoma, Mucinous
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCA-125 Antigen
dc.subject.meshCA-19-9 Antigen
dc.subject.meshCarcinoembryonic Antigen
dc.subject.meshDeoxycytidine
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMitomycin
dc.subject.meshPeritoneal Neoplasms
dc.subject.meshPseudomyxoma Peritonei
dc.subject.meshQuality of Life
dc.subject.meshSurvival Rate
dc.subject.meshTreatment Outcome
dc.titleA phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.en
dc.typeArticleen
dc.contributor.departmentPeritoneal Tumour Service, Department of Surgery, Christie Hospital NHS Foundation Trust, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractPseudomyxoma peritonei (PMP) is a rare neoplastic process characterised by progressive intra-abdominal dissemination of mucinous tumour, and generally considered resistant to systemic chemotherapy. A phase II study in patients with advanced unresectable PMP was undertaken to evaluate the combination of systemic concurrent mitomycin C (7 mg m(-2) i.v. on day 1) and capecitabine (1250 mg m(-2) b.d. on days 1-14) in a 3-weekly cycle (MCap). Response was determined by semiquantitative assessment of disease volume on serial computed tomographic (CT) scans and serum tumour marker (CEA, CA125, CA19-9) changes at 12 weeks. Between 2003 and 2006, 40 patients were recruited through a national centre for the treatment of peritoneal surface tumours. At baseline, 23 patients had progressive disease and 17 had stable disease. Of 39 assessable patients, 15 (38%, 95% confidence intervals (CIs): 25, 54%) benefited from chemotherapy in the form of either reductions in mucinous deposition or stabilisation of progressive pretreatment disease determined on CT scan. Notably, two patients, originally considered unresectable, following MCap and re-staging underwent potentially curative cytoreductive surgery. Grade 3/4 toxicity rates were low (6%, 95% CIs: 4, 9%). Twenty out of 29 assessed patients (69%, 95% CIs: 51, 83%) felt that their Global Health Status improved during chemotherapy. This is the first trial to demonstrate an apparent benefit of systemic chemotherapy in patients with advanced unresectable PMP.


This item appears in the following Collection(s)

Show simple item record